TY - CHAP
T1 - The Effects of Curcumin on the Side Effects of Anticancer Drugs in Chemotherapy
T2 - A Randomized Controlled Trial
AU - Panahi, Yunes
AU - Vahedian-Azimi, Amir
AU - Saadat, Alireza
AU - Togeh, Gholamreza
AU - Rahimibashar, Farshid
AU - Fetrat, Masoum Khosh
AU - Amirfakhrian, Hossein
AU - Moallem, Seyed Adel
AU - Majeed, Muhammed
AU - Sahebkar, Amirhossein
PY - 2021
Y1 - 2021
N2 - Curcumin, the active ingredient of the spice turmeric, has been shown to have anticancer activities in several preclinical and clinical studies. The prophylactic effect of curcumin against chemotherapy-induced damage and side effects was evaluated in a double-blind, placebo-controlled randomized trial. Eighty cancer patients on standard chemotherapy regimens were randomly assigned to receive curcumin as adjuvant therapy (500 mg per 12 hours) and matched control group to receive placebo for 9 weeks. Pre- and post-intervention, the changes in the health-related quality-of-Life (QoL) score (based on the University of Washington Quality-of-Life (UW-QoL) questionnaire, version 3), clinical symptoms, and hematological and biochemical parameters were assessed. Comparison between groups based on total QoL score showed that curcumin supplementation was not associated with improved QoL (P = 0.102). Hematological and biochemical analysis showed no statistical differences between the groups at the end of the trial (P > 0.05). However, during the trial, significant differences were observed in hemoglobin (Hb), hematocrit (HCT), lactic acid dehydrogenase (LDH), serum glutamic-oxaloacetic transaminase (SGOT), and anaplastic lymphoma kinase (ALK) between the groups (P < 0.05). Future studies in a larger homogenous population of cancer patients are required to confirm the adjuvant effect of curcumin on chemotherapy-induced QoL.
AB - Curcumin, the active ingredient of the spice turmeric, has been shown to have anticancer activities in several preclinical and clinical studies. The prophylactic effect of curcumin against chemotherapy-induced damage and side effects was evaluated in a double-blind, placebo-controlled randomized trial. Eighty cancer patients on standard chemotherapy regimens were randomly assigned to receive curcumin as adjuvant therapy (500 mg per 12 hours) and matched control group to receive placebo for 9 weeks. Pre- and post-intervention, the changes in the health-related quality-of-Life (QoL) score (based on the University of Washington Quality-of-Life (UW-QoL) questionnaire, version 3), clinical symptoms, and hematological and biochemical parameters were assessed. Comparison between groups based on total QoL score showed that curcumin supplementation was not associated with improved QoL (P = 0.102). Hematological and biochemical analysis showed no statistical differences between the groups at the end of the trial (P > 0.05). However, during the trial, significant differences were observed in hemoglobin (Hb), hematocrit (HCT), lactic acid dehydrogenase (LDH), serum glutamic-oxaloacetic transaminase (SGOT), and anaplastic lymphoma kinase (ALK) between the groups (P < 0.05). Future studies in a larger homogenous population of cancer patients are required to confirm the adjuvant effect of curcumin on chemotherapy-induced QoL.
KW - Cancer
KW - Chemotherapy
KW - Curcumin
KW - Quality of life
KW - Randomized controlled trial
UR - http://www.scopus.com/inward/record.url?scp=85122538874&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-73234-9_17
DO - 10.1007/978-3-030-73234-9_17
M3 - Chapter
C2 - 34981483
AN - SCOPUS:85122538874
SN - 978-3-030-73233-2
T3 - Advances in Experimental Medicine and Biology
SP - 255
EP - 273
BT - Natural Products and Human Diseases
A2 - Sahebkar, Amirhossein
A2 - Sathyapalan, Thozhukat
PB - Springer Heidelberg
CY - Switzerland
ER -
